Patient Safety Organizations: A Compliance Self-Assessment Guide, 48082-48083 [E9-22594]
Download as PDF
mstockstill on DSKH9S0YB1PROD with NOTICES
48082
Federal Register / Vol. 74, No. 181 / Monday, September 21, 2009 / Notices
Sara Luckhaupt at sluckhaupt@cdc.gov
or (513) 841–4123 for information about
how to register for the meeting.
ADDRESSES: Oral comments given at the
meeting will be recorded and included
in the NIOSH–187 docket. You may
submit comments, identified by docket
number NIOSH–187, by any of the
following methods:
• Mail: NIOSH Docket Office, Robert
A. Taft Laboratories, MS–C34, 4676
Columbia Parkway, Cincinnati, OH
45226.
• Facsimile: (513) 533–8285.
• E-mail: nioshdocket@cdc.gov.
All information received in response to
this notice will be available for public
examination and copying at the NIOSH
Docket Office, 4676 Columbia Parkway,
Cincinnati, Ohio 45226. A complete
electronic docket containing all
comments submitted will be available
on the NIOSH Web page at https://
www.cdc.gov/niosh/docket, and
comments will be available in writing
by request. NIOSH includes all
comments received without change in
the docket, including any personal
information provided.
Background: The NHSN is an
Internet-based surveillance system
established in 2005 by the CDC Division
of Healthcare Quality Promotion
(DHQP) that includes both patient safety
and healthcare personnel health and
safety modules. The proposed
enhancement to the NHSN will
electronically link and integrate a wide
variety of ongoing occupational health
surveillance activities and facilitate
more accurate and timely prevention
strategies, while meeting necessary
confidentiality and security
requirements.
This project focuses on surveillance
and prevention of four occupational
health outcomes among healthcare
workers: (1) Traumatic injuries in the
workplace (specifically: (a)
musculoskeletal disorders due to patient
handling and working in awkward
postures, (b) slips, trips, and falls, and
(c) workplace violence); (2) dermatitis
due to workplace exposures; (3) workrelated asthma; and (4) airborne
transmission of tuberculosis in the
workplace. Once these enhancements to
NHSN are successfully implemented,
additional occupational health metrics
can be added to the system to address
emerging problems such as pandemic
influenza.
The success of this project will
depend on the participation of
healthcare facilities in the surveillance
system. Because the stakeholders
themselves will be the central users of
our proposed additions to NHSN, they
VerDate Nov<24>2008
17:24 Sep 18, 2009
Jkt 217001
will be extensively involved in every
stage of this project—including initial
development, implementation, and
evaluation of the new module and event
forms. This meeting will provide an
opportunity for stakeholders to
contribute to the initial development of
the data collection forms.
FOR FURTHER INFORMATION CONTACT:
Ahmed Gomaa, Robert A. Taft
Laboratories, MS–R17, 4676 Columbia
Parkway, Cincinnati, OH 45226,
telephone (513) 841–4337, or Sara
Luckhaupt, same address, telephone
(513) 841–4123.
References: National Healthcare Safety
Network (NHSN)—https://
www.cdc.gov/nhsn/.
Healthcare Personnel Safety
Component—https://www.cdc.gov/
nhsn/hps.html.
Dated: September 14, 2009.
Tanja Popovic,
Chief Science Officer, Centers for Disease
Control and Prevention.
[FR Doc. E9–22656 Filed 9–18–09; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Patient Safety Organizations: A
Compliance Self-Assessment Guide
AGENCY: Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of Availability—Patient
Safety Organizations: A Compliance
Self-Assessment Guide.
SUMMARY: AHRQ is announcing the
availability of a document entitled:
‘‘Patient Safety Organizations: A
Compliance Self-Assessment Guide.’’
The Patient Safety and Quality
Improvement Act of 2005, Public Law
109–41, 42 U.S.C. 299–b21—b–26
(Patient Safety Act) provides for the
formation of Patient Safety
Organizations (PSOs), which collect,
aggregate, and analyze confidential
information regarding the quality and
safety of healthcare delivery. The
Patient Safety and Quality Improvement
Final Rule (Patient Safety Rule) (42 CFR
part 3) authorizes AHRQ, on behalf of
the Secretary of HHS, to: list as a PSO
an entity that attests that it meets the
statutory and regulatory requirements
for listing; and request additional
information and conduct reviews
(including announced or unannounced
site visits) to assess PSO compliance. To
assist PSOs in making the required
attestations and preparing for a
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
compliance review, AHRQ developed
the sample questions in this guide to
encourage each PSO to take a thorough
and systematic approach to compliance.
The guide recognizes that each PSO’s
approach to compliance may be
different based upon the specific
mission it has chosen, the specific
activities and expertise it offers to
healthcare providers, and its size and
mode of operation. Thus, these
questions are merely illustrative; some
questions will not be applicable or even
appropriate for every PSO. The guide
does not establish new standards or
requirements beyond those that are
established by the Patient Safety Rule.
DATES: Availability of resource.
ADDRESSES: ‘‘Patient Safety
Organizations: A Compliance SelfAssessment Guide’’ can be accessed
electronically at the following HHS Web
site: https://www.pso.ahrg.qov/
index.html.
FOR FURTHER INFORMATION CONTACT:
Diane Cousins, RPh., Center for Quality
Improvement and Patient Safety, AHRQ,
540 Gaither Road, Rockville, MD 20850;
Telephone (toll free): (866) 403–3697;
Telephone (local): (301) 427 1111; TTY
(toll free): (866) 438–7231; TTY (local):
(301) 427–1130; E-mail:
pso@ahrq.hhs.qov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act establishes a
framework by which healthcare
providers can report information
voluntarily to PSOs, on a privileged and
confidential basis, for the aggregation
and analysis of patient safety events and
quality concerns. A PSO is an entity
listed by the Secretary of HHS, which
has a primary focus to conduct activities
to improve patient safety and the quality
of healthcare delivery.
The requirements governing PSOs are
set forth in subpart B of the Patient
Safety Rule. These include: the
requirements that an entity must meet to
become, and remain listed, as a PSO; the
procedures and processes for assessing
an entity’s eligibility; the processes for
ensuring a PSO’s compliance with the
requirements of the Patient Safety Rule,
and for correcting deficiencies in a
PSO’s compliance; and the process by
which a PSO can voluntarily relinquish
its listing or, in the case of a PSO that
does not correct one or more
deficiencies, the process for delisting a
PSO for cause. Within the framework
established by the Patient Safety Act,
PSOs are a source of expert advice for
providers, and PSOs enable providers to
take advantage of the potential for
significant aggregation of patient safety
E:\FR\FM\21SEN1.SGM
21SEN1
mstockstill on DSKH9S0YB1PROD with NOTICES
Federal Register / Vol. 74, No. 181 / Monday, September 21, 2009 / Notices
events within the protections of the
Patient Safety Act and Patient Safety
Rule. As a result, healthcare providers,
and those committed to improving the
safety and quality of patient care, have
a strong interest in the integrity of PSOs
and their ability to carry out this
statutory mission.
AHRQ administers the provisions of
the Patient Safety Rule relating to listing
and operation of PSOs, which are the
focus of this guide. The HHS Office for
Civil Rights is responsible for enforcing
the confidentiality protections of the
Patient Safety Act and Patient Safety
Rule.
For an entity to be listed, and remain
listed, as a PSO, the Patient Safety Rule
relies primarily upon a system of
attestations. An entity seeking listing for
a three-year period as a PSO must
submit to AHRQ a form, Certification for
Initial Listing, to attest that it meets the
Patient Safety Rule’s eligibility and
listing requirements at the time the
entity submits its certifications. During
its period of listing, a PSO must submit
a form, Two Bona Fide Contract
Requirement, every two years attesting
that it has at least two contracts with
different providers. If the PSO has other
relationships, specified in section
3.102(d)(2), with any contracting
provider, it must also submit the form,
PSO Disclosure Statement, regarding its
relationships with the provider and
attest to the completeness and accuracy
of its disclosures. Finally, a PSO must
submit the form, Certification for
Continued Listing, to seek continued
listing for an additional three-year
period and attest that it meets the
requirements for continued listing. This
process places the burden for
understanding and complying with the
Patient Safety Rule on the PSO.
The Patient Safety Rule also
authorizes AHRQ to assess or verify
PSO compliance with the rule’s
requirements at any time through
requests for information or by
conducting announced or unannounced
reviews of, or site visits to, PSOs
(section 3.110). In addition to routine
compliance reviews, AHRQ may also
conduct site visits or request additional
information if, for example, AHRQ
becomes aware that a PSO is not in
compliance with the requirements of the
statute or the Patient Safety Rule.
The Patient Safety Rule provides
PSOs latitude in complying with its
requirements. In part, this reflects a
recognition that PSOs will vary in terms
of size, complexity, and sophistication
and, over time, PSOs will vary
significantly in the breadth and scope of
their activities. For example, PSOs can
be local, regional, or national in
VerDate Nov<24>2008
17:24 Sep 18, 2009
Jkt 217001
orientation; they can focus narrowly or
broadly in terms of the clinical or
analytic services they offer providers;
they can target their services toward one
type of healthcare facility or multiple
healthcare settings; and, they are likely
to vary in the sophistication and
complexity of information technology
employed.
Each PSO will need to develop its
approach to compliance by taking into
account the specific mission it has
chosen for itself, the specific activities
and expertise it offers to healthcare
providers, and its size and mode of
operation. As a consequence, AHRQ
developed this self-assessment guide
recognizing that individual PSOs are
likely to approach compliance from
different perspectives. Thus, the guide
does not propose a uniform approach to
compliance, Instead, the guide presents
sample questions—some of which may
not be applicable or appropriate to a
specific PSO—to encourage each PSO to
take a comprehensive and systematic
approach to compliance that best meets
its circumstances.
The questions in the guide do not
establish new standards or
requirements; they are only presented
for an illustrative purpose. If there is
any inadvertent discrepancy between
the text of the guide and the Patient
Safety Rule, PSOs should consider the
text of the rule as authoritative.
More information on the ‘‘Patient
Safety Organizations: A Compliance Self
Assessment Guide’’ and PSOs can be
obtained through AHRQ’s PSO Web site:
https://www.pso.ahrq.qov/.
Dated: September 11, 2009.
Carolyn M. Clancy,
Director.
[FR Doc. E9–22594 Filed 9–18–09; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0441]
Promotion of Food and Drug
Administration-Regulated Medical
Products Using the Internet and Social
Media Tools; Notice of Public Hearing
AGENCY:
Food and Drug Administration,
HHS.
ACTION: Notice of public hearing;
request for comments.
SUMMARY: The Food and Drug
Administration’s (FDA’s) Center for
Drug Evaluation and Research (CDER),
in collaboration with FDA’s Center for
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
48083
Biologics Evaluation and Research
(CBER), Center for Veterinary Medicine
(CVM), and Center for Devices and
Radiological Health (CDRH), is
announcing a public hearing to discuss
issues related to the promotion of FDAregulated medical products (including
prescription drugs for humans and
animals, prescription biologics, and
medical devices) using the Internet and
social media tools. FDA is seeking
participation in the public hearing and
written comments from all interested
parties, including, but not limited to,
consumers, patients, caregivers, health
care professionals, patient groups,
Internet vendors, advertising agencies,
and the regulated industry. This
meeting and the written comments are
intended to help guide FDA in making
policy decisions on the promotion of
human and animal prescription drugs
and biologics and medical devices using
the Internet and social media tools. FDA
is seeking input on a number of specific
questions but is interested in any other
pertinent information participants in the
hearing would like to share.
Dates and Times: The public hearing
will be held on November 12 and 13,
2009, from 8 a.m. to 5 p.m. each day.
Submit written or electronic registration
by close of business on October 9, 2009.
Written and electronic comments will
be accepted until February 28, 2010.
Location: The public hearing will be
held at the National Transportation
Safety Board Conference Center, 429
L’Enfant Plaza, SW., Washington, DC
20594, 202–314–6305; Metro: L’Enfant
Plaza station on the yellow, green,
orange, and blue lines; see: https://
ntsb.gov/events/newlocation.htm. (FDA
has verified the Web site address, but
FDA is not responsible for any changes
to the Web site after this document
publishes in the Federal Register.)
ADDRESSES: Submit written registration
and written comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
Submit electronic registration and
electronic comments, identified with
the docket number found in brackets in
the heading of this document, to https://
www.regulations.gov.
Transcripts of the hearing will be
available for review at the Division of
Dockets Management and on the
Internet at https://www.regulations.gov
approximately 30 days after the hearing
(see section VI of this document).
Registration to Attend and/or to
Participate in the Meeting: Seating at the
hearing is limited. People interested in
attending should submit written or
electronic registration as specified above
E:\FR\FM\21SEN1.SGM
21SEN1
Agencies
[Federal Register Volume 74, Number 181 (Monday, September 21, 2009)]
[Notices]
[Pages 48082-48083]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-22594]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: A Compliance Self-Assessment Guide
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Notice of Availability--Patient Safety Organizations: A
Compliance Self-Assessment Guide.
-----------------------------------------------------------------------
SUMMARY: AHRQ is announcing the availability of a document entitled:
``Patient Safety Organizations: A Compliance Self-Assessment Guide.''
The Patient Safety and Quality Improvement Act of 2005, Public Law 109-
41, 42 U.S.C. 299-b21--b-26 (Patient Safety Act) provides for the
formation of Patient Safety Organizations (PSOs), which collect,
aggregate, and analyze confidential information regarding the quality
and safety of healthcare delivery. The Patient Safety and Quality
Improvement Final Rule (Patient Safety Rule) (42 CFR part 3) authorizes
AHRQ, on behalf of the Secretary of HHS, to: list as a PSO an entity
that attests that it meets the statutory and regulatory requirements
for listing; and request additional information and conduct reviews
(including announced or unannounced site visits) to assess PSO
compliance. To assist PSOs in making the required attestations and
preparing for a compliance review, AHRQ developed the sample questions
in this guide to encourage each PSO to take a thorough and systematic
approach to compliance. The guide recognizes that each PSO's approach
to compliance may be different based upon the specific mission it has
chosen, the specific activities and expertise it offers to healthcare
providers, and its size and mode of operation. Thus, these questions
are merely illustrative; some questions will not be applicable or even
appropriate for every PSO. The guide does not establish new standards
or requirements beyond those that are established by the Patient Safety
Rule.
DATES: Availability of resource.
ADDRESSES: ``Patient Safety Organizations: A Compliance Self-Assessment
Guide'' can be accessed electronically at the following HHS Web site:
https://www.pso.ahrg.qov/.
FOR FURTHER INFORMATION CONTACT: Diane Cousins, RPh., Center for
Quality Improvement and Patient Safety, AHRQ, 540 Gaither Road,
Rockville, MD 20850; Telephone (toll free): (866) 403-3697; Telephone
(local): (301) 427 1111; TTY (toll free): (866) 438-7231; TTY (local):
(301) 427-1130; E-mail: pso@ahrq.hhs.qov.
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act establishes a framework by which healthcare
providers can report information voluntarily to PSOs, on a privileged
and confidential basis, for the aggregation and analysis of patient
safety events and quality concerns. A PSO is an entity listed by the
Secretary of HHS, which has a primary focus to conduct activities to
improve patient safety and the quality of healthcare delivery.
The requirements governing PSOs are set forth in subpart B of the
Patient Safety Rule. These include: the requirements that an entity
must meet to become, and remain listed, as a PSO; the procedures and
processes for assessing an entity's eligibility; the processes for
ensuring a PSO's compliance with the requirements of the Patient Safety
Rule, and for correcting deficiencies in a PSO's compliance; and the
process by which a PSO can voluntarily relinquish its listing or, in
the case of a PSO that does not correct one or more deficiencies, the
process for delisting a PSO for cause. Within the framework established
by the Patient Safety Act, PSOs are a source of expert advice for
providers, and PSOs enable providers to take advantage of the potential
for significant aggregation of patient safety
[[Page 48083]]
events within the protections of the Patient Safety Act and Patient
Safety Rule. As a result, healthcare providers, and those committed to
improving the safety and quality of patient care, have a strong
interest in the integrity of PSOs and their ability to carry out this
statutory mission.
AHRQ administers the provisions of the Patient Safety Rule relating
to listing and operation of PSOs, which are the focus of this guide.
The HHS Office for Civil Rights is responsible for enforcing the
confidentiality protections of the Patient Safety Act and Patient
Safety Rule.
For an entity to be listed, and remain listed, as a PSO, the
Patient Safety Rule relies primarily upon a system of attestations. An
entity seeking listing for a three-year period as a PSO must submit to
AHRQ a form, Certification for Initial Listing, to attest that it meets
the Patient Safety Rule's eligibility and listing requirements at the
time the entity submits its certifications. During its period of
listing, a PSO must submit a form, Two Bona Fide Contract Requirement,
every two years attesting that it has at least two contracts with
different providers. If the PSO has other relationships, specified in
section 3.102(d)(2), with any contracting provider, it must also submit
the form, PSO Disclosure Statement, regarding its relationships with
the provider and attest to the completeness and accuracy of its
disclosures. Finally, a PSO must submit the form, Certification for
Continued Listing, to seek continued listing for an additional three-
year period and attest that it meets the requirements for continued
listing. This process places the burden for understanding and complying
with the Patient Safety Rule on the PSO.
The Patient Safety Rule also authorizes AHRQ to assess or verify
PSO compliance with the rule's requirements at any time through
requests for information or by conducting announced or unannounced
reviews of, or site visits to, PSOs (section 3.110). In addition to
routine compliance reviews, AHRQ may also conduct site visits or
request additional information if, for example, AHRQ becomes aware that
a PSO is not in compliance with the requirements of the statute or the
Patient Safety Rule.
The Patient Safety Rule provides PSOs latitude in complying with
its requirements. In part, this reflects a recognition that PSOs will
vary in terms of size, complexity, and sophistication and, over time,
PSOs will vary significantly in the breadth and scope of their
activities. For example, PSOs can be local, regional, or national in
orientation; they can focus narrowly or broadly in terms of the
clinical or analytic services they offer providers; they can target
their services toward one type of healthcare facility or multiple
healthcare settings; and, they are likely to vary in the sophistication
and complexity of information technology employed.
Each PSO will need to develop its approach to compliance by taking
into account the specific mission it has chosen for itself, the
specific activities and expertise it offers to healthcare providers,
and its size and mode of operation. As a consequence, AHRQ developed
this self-assessment guide recognizing that individual PSOs are likely
to approach compliance from different perspectives. Thus, the guide
does not propose a uniform approach to compliance, Instead, the guide
presents sample questions--some of which may not be applicable or
appropriate to a specific PSO--to encourage each PSO to take a
comprehensive and systematic approach to compliance that best meets its
circumstances.
The questions in the guide do not establish new standards or
requirements; they are only presented for an illustrative purpose. If
there is any inadvertent discrepancy between the text of the guide and
the Patient Safety Rule, PSOs should consider the text of the rule as
authoritative.
More information on the ``Patient Safety Organizations: A
Compliance Self Assessment Guide'' and PSOs can be obtained through
AHRQ's PSO Web site: https://www.pso.ahrq.qov/.
Dated: September 11, 2009.
Carolyn M. Clancy,
Director.
[FR Doc. E9-22594 Filed 9-18-09; 8:45 am]
BILLING CODE 4160-90-M